Importantly, ROF treatment significantly suppressed tumor growth <i>in vivo</i> without discernible toxicity.<h4>Conclusion</h4>Rhoifolin exerts potent and selective anti-lung cancer activity by directly targeting and downregulating EPHB2, providing a strong rationale for its further development as a novel therapeutic agent for lung cancer. This evidence concerns the gene EPHB2 and neoplasm.